Around 83% of clinicians favored empagliflozin over other SGLT2 inhibitors, citing its superior efficacy, safety, and real-world performance supported by the evidences from the EMPA-REG OUTCOME trial which demonstrated significant reductions in cardiovascular mortality and HF hospitalization [30], while real-world data from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) further supported its favorable profile [39]. The gene discussed is SLC5A2; the disease is hydrops fetalis.